INTRODUCTION
OBJECTIVES AND GOALS OF STUDY
Regenerative medicine refers to technologies that repair or replace diseased or defective tissues
or organs. The main types of regenerative medicine utilize products naturally occurring in the body, such as genes and proteins (antibodies, growth
factors, hormones); cells and tissues; embryonic stem cells, and biomaterials. At present, most regenerative medicines on the market fall into the
first category and include protein-based drugs and therapies containing human cells. However, there are a few products based on tissue engineering.
This technology, which promises to be the most exciting and fastest growing sector of regenerative medicine in the near future, is the primary focus
of this report. Tissue engineering technologies discussed include matrices and scaffolds, in vitro and in vivo technologies, and novel materials,
which include those utilizing nanotechnology (atomic-scale engineering) of inorganic substances that meld with human tissues.
This report focuses
on the bone- and joint-related applications of and markets for the various types of regenerative medicine currently available and projected to be
introduced during the forecast period (2001 to 2007). Market drivers discussed include an increase in diseases and disorders that will benefit from
these products, primarily arthritis, osteoporosis, and various types of bone and joint trauma (hip fractures, knee injuries, etc.); increasing use of
nonautograft products by physicians; and innovative devices that incorporate bone- and cartilage-growth stimulating agents in a regenerative
appliance. Products discussed include bone and cartilage grafting and regenerative products derived from autologous, allogeneic and synthetic sources
as well as electronic bone growth stimulators and regenerative cartilage products. Profiles of leading and emerging companies in the bone and joint
regenerative medicine markets are provided, along with analysis of the current and future positioning of their products and businesses in this active
and rapidly changing market.
CONTRIBUTION OF THE STUDY AND FOR WHOM
The aim of this report is to provide an overview of
regenerative medicine products available and emerging for the treatment of diseases and disorders of the bones and joints.
The information and
analysis presented are an important asset in decision-making for managers involved in business development, marketing, market research, product
development, mergers and acquisitions, licensing, business management, investment banking and deal creation, and to consultants to the pharmaceutical
and biotechnology industries. The study provides a comprehensive analysis of the current markets for regenerative medicine products for bones and
joints, relevant applications, and the potential of products in development.
STUDY SCOPE AND FORMAT
- The scope of the study is worldwide. The Overview section provides a background of the demographics underlying the market for bone and joint
products, a definition of regenerative medicine and the technologies involved, and a discussion of regenerative products in development for
applications other than bones and joints.
- The Applications section describes the leading bone and joint diseases and disorders applicable to regenerative technologies, including
incidence and current methods of treatment.
- The section on Products provides extensive descriptions and analysis (including comparative analysis) of regenerative products used to treat
bone and joint disorders as well as discussion of products in development.
- The section on Industry provides a discussion of regulatory issues affecting regenerative medicine products as well as recent bankruptcies among
companies supplying regenerative products and the reasons for their financial difficulties.
- The Company Profiles section provides a concise exploration of leading and emerging companies in the area of regenerative products for bones and
joints, including product introductions, patents, and overall business strategies.
METHODOLOGY
The base year for this study is 2002. Figures are based on revenue figures at the manufacturer's level and are
projected at 2002 dollar values, that is, inflation is not computed into the projection figures.
Information to prepare this study was derived
from information provided by chief executive officers, marketing strategists, research executives and others at leading companies involved in the
regenerative medicine market. Data was accessed from government agencies and regulatory bodies that monitor and/or regulate medical devices. Searches
of secondary material such as company annual reports and 10Ks, journal articles, prospectus assessments, government resources and data from healthcare
institutions were also conducted.
INFORMATION SOURCES
The information and analysis presented in this report are based on an
extensive survey of the biotechnology and pharmaceutical industries as well as a detailed examination of published literature and reports obtained
from regulatory authorities, medical research institutions, pharmaceutical trade associations and national and world health organizations.
View Cart
